Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Reneo Pharmaceuticals (RPHM)
NASDAQ:RPHM
RESEARCH TOOLSreports
Reneo Pharmaceuticals (RPHM) Stock Price & Analysis
222 Followers
RPHM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.98 - $9.45
Previous Close$1.75
Volume284.46K
Average Volume (3M)278.42K
Market Cap
$58.49M
Enterprise Value-$65.99M
Total Cash (Recent Filing)$125.61M
Total Debt (Recent Filing)$1.14M
Price to Earnings (P/E)-0.8
Beta0.45
Next Earnings
Aug 07, 2024EPS Estimate
-$0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.17
Shares Outstanding33,420,808
10 Day Avg. Volume958,808
30 Day Avg. Volume278,415
Standard Deviation0.31
R-Squared0.00139
Alpha-0.00881
Financial Highlights & Ratios
Price to Book (P/B)0.51
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda1.31
Forecast
1Y Price Target
$1.23Price Target Upside-35.26% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering3
Reneo Pharmaceuticals News
PremiumCompany Announcements
Reneo Pharmaceuticals Announces Merger and Strategic PIPE Investment
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company is expected to have a robust financial position with significant cash and equivalents post-closing.
Product DevelopmentPreclinical results look encouraging for OnKure's allosteric mutant-selective inhibitor, indicating potential for breakthrough in cancer treatment.
Strategic DirectionMerger with OnKure pivots story towards oncology.
Bears Say
Corporate StrategyManagement’s announcement that they had retained an independent financial advisor to evaluate potential strategic alternatives suggests uncertainty in the company's future direction.
Drug DevelopmentThe company suspended mavodelpar development after the pivotal Phase 2b STRIDE study did not meet either primary or secondary efficacy endpoint.
Financial PerformanceRPHM reported a net loss, which could reflect negatively on the company's financial health and investor confidence.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
RPHM FAQ
What was Reneo Pharmaceuticals’s price range in the past 12 months?
Reneo Pharmaceuticals lowest stock price was $0.98 and its highest was $9.45 in the past 12 months.
What is Reneo Pharmaceuticals’s market cap?
Currently, no data Available
When is Reneo Pharmaceuticals’s upcoming earnings report date?
Reneo Pharmaceuticals’s upcoming earnings report date is Aug 07, 2024 which is in 78 days.
How were Reneo Pharmaceuticals’s earnings last quarter?
Reneo Pharmaceuticals released its earnings results on May 07, 2024. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.437 by $0.187.
Is Reneo Pharmaceuticals overvalued?
According to Wall Street analysts Reneo Pharmaceuticals’s price is currently Overvalued.
Does Reneo Pharmaceuticals pay dividends?
Reneo Pharmaceuticals does not currently pay dividends.
What is Reneo Pharmaceuticals’s EPS estimate?
Reneo Pharmaceuticals’s EPS estimate is -$0.13.
How many shares outstanding does Reneo Pharmaceuticals have?
Reneo Pharmaceuticals has 33,420,807 shares outstanding.
What happened to Reneo Pharmaceuticals’s price movement after its last earnings report?
Reneo Pharmaceuticals reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.437. Following the earnings report the stock price went up 0.578%.
Which hedge fund is a major shareholder of Reneo Pharmaceuticals?
Among the largest hedge funds holding Reneo Pharmaceuticals’s share is Highbridge Capital Management LLC. It holds Reneo Pharmaceuticals’s shares valued at 5M.
---
Reneo Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$1.23 (-35.26% Downside)
$1.23 (-35.26% Downside)
Blogger Sentiment
Bullish
RPHM Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $639.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.70%
12-Months-Change
Fundamentals
Return on Equity
-84.01%
Trailing 12-Months
Asset Growth
-14.39%
Trailing 12-Months
Company Description
Reneo Pharmaceuticals
Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
---
RPHM Stock 12 Month Forecast
Average Price Target
$1.23
▼(-35.26% Downside)
Technical Analysis
Best Analysts Covering RPHM
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-49.63%
reiterated a sell rating 2 months ago
Copying Jason Zemansky's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -49.63% per trade.
---